uniQure N.V. (NASDAQ:QURE) has been given a consensus rating of “Hold” by the nine brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $13.25.
QURE has been the topic of several research reports. Cowen and Company restated a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Oppenheimer Holdings, Inc. set a $17.00 price target on shares of uniQure N.V. and gave the stock a “buy” rating in a research report on Tuesday, May 16th. Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the stock a “buy” rating in a research report on Sunday, July 23rd. ValuEngine upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research cut shares of uniQure N.V. from a “buy” rating to a “hold” rating in a research report on Thursday, August 24th.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://weekherald.com/2017/09/13/uniqure-n-v-qure-given-average-rating-of-hold-by-analysts.html.
Shares of uniQure N.V. (NASDAQ QURE) traded down 1.95% during midday trading on Wednesday, reaching $8.04. 43,845 shares of the company’s stock traded hands. The company has a 50-day moving average of $8.24 and a 200-day moving average of $6.41. uniQure N.V. has a one year low of $4.72 and a one year high of $9.15. The company’s market capitalization is $205.50 million.
uniQure N.V. (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.05). uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $2.92 million. Equities research analysts anticipate that uniQure N.V. will post ($3.08) EPS for the current year.
In other uniQure N.V. news, insider Harald Petry sold 58,075 shares of uniQure N.V. stock in a transaction on Monday, June 26th. The shares were sold at an average price of $6.01, for a total transaction of $349,030.75. Following the completion of the transaction, the insider now directly owns 155 shares of the company’s stock, valued at $931.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 173,460 shares of company stock valued at $1,042,986 over the last ninety days. 0.73% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Oxford Asset Management purchased a new stake in shares of uniQure N.V. during the first quarter valued at $100,000. Mangrove Partners purchased a new stake in shares of uniQure N.V. during the second quarter valued at $247,000. JPMorgan Chase & Co. boosted its stake in shares of uniQure N.V. by 50.5% during the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 14,702 shares during the period. Weiss Multi Strategy Advisers LLC boosted its stake in shares of uniQure N.V. by 266.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock valued at $318,000 after purchasing an additional 40,000 shares during the period. Finally, Paloma Partners Management Co boosted its stake in shares of uniQure N.V. by 717.7% during the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after purchasing an additional 74,605 shares during the period. 29.86% of the stock is owned by hedge funds and other institutional investors.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.